NovavaxXSWX:NVAX -1.78%50 Days Payable is 60.91 as of Mar. 2026, which is 62% below its 10-year median of 161.05. GuruFocus rates XSWX:NVAX with a GF Score™ of 50/100 and a GF Value™ of CHF3.14. The stock has 7 warning signs investors should review. Among 700 Biotechnology companies, Novavax ranks better than 50.43% on this metric.
Novavax's average Accounts Payable for the
three
months ended in Mar. 2026 was CHF16.1 Mil. Novavax's Cost of Goods Sold for the
three
months ended in Mar. 2026 was CHF24.2 Mil.
Hence, Novavax's Days Payable for the
three
months ended in Mar. 2026 was 60.91.
The historical rank and industry rank for Novavax's Days Payable or its related term are showing as below:
XSWX:NVAX'
s Days Payable Range Over the Past 10 Years
Min: 69.46 Med: 161.05 Max: 185.34
Current: 114.58
During the past 13 years, Novavax's highest Days Payable was 185.34. The lowest was 69.46. And the median was 161.05.
XSWX:NVAX's Days Payable is ranked better than 50.43% of 700
companies
in the Biotechnology industry
Industry Median: 113.1
vs XSWX:NVAX: 114.58
Novavax's Days Payable
declined
from Mar. 2025 (246.04) to Mar. 2026 (60.91).
It may suggest that Novavaxaccelerated paying its suppliers.
Novavax Days Payable Related Terms
Novavax Days Payable Historical Data
* Premium members only.
The historical data trend for Novavax's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:NVAX vs MPLT, COAG, INBX: Days Payable Comparison
For the Biotechnology subindustry, Novavax's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novavax Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novavax's Days Payable distribution charts can be found below:
* The bar in red indicates where Novavax's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Novavax's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novavax (XSWX:NVAX) has a Days Payable of 60.91 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Novavax and its competitors. This is 62% below median its historical median of 161.05. Over the past decade, Novavax's Days Payable has ranged from 69.46 to 185.34. According to the industry distribution chart, Novavax ranks #347 out of 700 companies in the Biotechnology industry, placing it in the top 49.6%.
Is Novavax's Days Payable too high?
Novavax's current Days Payable of 60.91 is 62% below median its 10-year median of 161.05. Over the past 10 years, this metric has ranged from a low of 69.46 to a high of 185.34. The Biotechnology industry median Days Payable is 113.10. Novavax's value of 60.91 is 46.1% below this industry median. Based on the distribution chart, Novavax ranks #347 out of 700 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Novavax has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Novavax's Days Payable compare to MPLT and COAG?
According to the Biotechnology industry distribution chart, Novavax ranks #347 out of 700 companies for Days Payable. This puts Novavax in the upper half of its industry. The industry median Days Payable is 113.10. Novavax's value of 60.91 is 46.1% below this benchmark. Historically, Novavax's own Days Payable has ranged from 69.46 to 185.34 over the past decade. While the company's 10-year median is 161.05 vs. the industry median of 113.10, Novavax has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novavax's current Days Payable of 60.91 is 46.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Novavax and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novavax's current Days Payable is 60.91, which is 62% below median its own 10-year median of 161.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Novavax (XSWX:NVAX) has a current Days Payable of 60.91. The stock's GF Value™ is CHF3.14, compared to a current price of CHF7.61 — trading 142.4% above its estimated fair value. The current Days Payable is 60.91, which is 62% below median its 10-year median of 161.05 and 46.1% below the Biotechnology industry median of 113.10. Novavax's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Novavax (XSWX:NVAX), the current Days Payable is 60.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novavax (XSWX:NVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Novavax stock appears to be overvalued.
The current stock price of CHF7.61 is trading 142.4% above its estimated GF Value™ of CHF3.14.
Key valuation signals for XSWX:NVAX:
Days Payable: 60.91 (62% below median its 10-year median of 161.05)
GF Value™: CHF3.14 vs. price of CHF7.61 (142.4% above fair value)
Industry Position: 46.1% below the Biotechnology median (#347 of 700)
No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
50GF Score
Get the complete analysis for XSWX:NVAX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:NVAX has been successfully added to your 
